In this issue:
- Excision keratinocyte cancer pathways by teledermatology in Waikato
- Pembrolizumab ± neoantigen mRNA-4157 for resected melanoma
- RT ± immunotherapy for metastatic melanoma
- ICI therapy for advanced cutaneous SCC in Australia
- Cemiplimab in metastatic BCC after HHIs
- Neoadjuvant toripalimab + axitinib in resectable mucosal melanoma
- BCC, SCC and SCC in situ survival
- Health-related QOL in resected stage III–IV melanoma treated with adjuvant anti-PD1
- Skin cancer in psoriasis, vitiligo or mycosis fungoides treated with NB-UVB
- Gut microbiome changes in ICI-treated advanced melanoma
Please login below to download this issue (PDF)